

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <http://orca.cf.ac.uk/92751/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Gabbiani, Chiara, Pratesi, Alessandro, Marchetti, Lorella, Casini, Angela, Leoni, Piero, Pillozzi, Serena, Crociani, Olivia, Bartoli, Gianluca and Messori, Luigi 2016. Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells. *Journal of Inorganic Biochemistry* 163 , pp. 318-322. 10.1016/j.jinorgbio.2016.06.024 file

Publishers page: <http://dx.doi.org/10.1016/j.jinorgbio.2016.06.024>
<<http://dx.doi.org/10.1016/j.jinorgbio.2016.06.024>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.





Contents lists available at ScienceDirect

Journal of Inorganic Biochemistry

journal homepage: www.elsevier.com/locate/jinorgbio

Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells

Chiara Gabbiani^a, Alessandro Pratesi^{b,*}, Lorella Marchetti^a, Angela Casini^c, Piero Leoni^a, Serena Pillozzi^d, Olivia Crociani^d, Gianluca Bartoli^d, Luigi Messori^{b,*}

^a Department of Chemistry and Industrial Chemistry, University of Pisa, via Risorgimento 35, 56126 Pisa, Italy

^b Laboratory of Metals in Medicine, Department of Chemistry, University of Florence, via della Lastruccia 3, 50019 Sesto Fiorentino, Florence, Italy

^c School of Chemistry, Cardiff University, Main Building, Park place, Cardiff CF10 3AT, United Kingdom

^d Department of Experimental and Clinical Medicine, University of Florence, Viale G.B. Morgagni 50, Florence, Italy

ARTICLE INFO

Article history:

Received 26 January 2016

Received in revised form 14 June 2016

Accepted 23 June 2016

Available online xxx

Keywords:

Pt clusters

Cytotoxicity

Mass spectrometry

Cancer

ABSTRACT

The trinuclear platinum cluster $[\text{Pt}_3(\mu\text{-PBU}^t_2)_3(\text{CO})_3]\text{CF}_3\text{SO}_3$ (**I**) was designed featuring the presence of a nearly equilateral platinum triangle bridged by three di-*tert*-butylphosphide ligands; in addition, each platinum center bears a terminal carbonyl ligand. This triplatinum cluster was initially developed in view of applications in the field of cluster-containing innovative materials. Yet, due to the large success of platinum complexes in cancer treatment, we also decided to explore its cytotoxic and anticancer properties. Accordingly, the solubility profile of this compound in several solvents was preliminarily investigated, revealing a conspicuous solubility in DMSO and DMSO/buffer mixtures; this makes the biological testing of **I** amenable. UV–Vis measurements showed that the triplatinum cluster is stable for several hours under a variety of conditions, within aqueous environments. No measurable reactivity was observed for **I** toward two typical model proteins, i.e. lysozyme and cytochrome c. On the contrary, a significant reactivity was evidenced when reacting **I** with small sulfur-containing ligands. In particular, a pronounced reactivity with reduced glutathione and cysteine emerged from ESI-MS experiments, proving complete formation of **I**-GSH and **I**-Cys derivatives, with the loss of a single carbonyl ligand. Starting from these encouraging results, the cytotoxic potential of **I** was assayed in vitro against a panel of representative cancer cell lines, and potent cytotoxic properties were disclosed. Of particular interest is the finding that the triplatinum species manifests potent antiproliferative properties toward Triple Negative Breast Cancer Cells, often refractory to most anticancer drugs. Owing to the reported encouraging results, a more extensive biological and pharmacological evaluation of this Pt cluster is now warranted to better elucidate its mode of action.

Crown Copyright © 2016 Published by Elsevier Inc. All rights reserved.

1. Introduction

Molecular platinum clusters have been intensely investigated during the last three decades for their attractive and peculiar chemical and electronic properties [1–4]. A variety of Pt clusters were thus prepared and characterised mostly containing a number of Pt atoms ranging from 3 to 50 [5–8]. In spite of these intense research activities and of extensive literature reports, we realised that this kind of compounds were poorly considered for their biological actions. This situation probably arises from the fact that Pt clusters are usually insoluble in aqueous environments and thus scarcely amenable for biomedical applications. In addition, their main application has been, traditionally, as models of heterogeneous platinum catalysts [9–11].

Yet, as platinum drugs play a key role in the current chemotherapeutic treatments of several cancers and as thousands of Pt analogues have been prepared and tested so far for this purpose, we wanted to ascertain whether selected Pt clusters might be of interest as prospective anticancer agents. The triplatinum cluster $[\text{Pt}_3(\mu\text{-PBU}^t_2)_3(\text{CO})_3]\text{CF}_3\text{SO}_3$ (**I**), prepared and characterised a few years ago in our laboratory [12], appeared to be a good candidate for this kind of investigations. Its crystal structure had been solved earlier, and a model of the cation is shown in Fig. 1. This complex consists of three equidistant platinum centers connected through bridging P donors belonging to three di-*tert*-butylphosphide ligands; in turn, each platinum center bears a carbonyl ligand.

This monocationic triplatinum cluster was first developed in view of its use as a building block for the synthesis of cluster-containing molecular assemblies [13]. However, as it also manifests an appreciable stability in solution and sufficient solubility even in aqueous environments, we wondered whether it might be suitable for biomedical applications.

These arguments led us to study in more detail the solution behaviour of **I** and to characterise its reactivity toward a few standard biomolecules. Afterward, the antiproliferative and pro-apoptotic properties of **I**

* Corresponding authors at: Department of Chemistry, University of Florence, Via della Lastruccia 3, 50019 Sesto Fiorentino, Italy.

E-mail addresses: alessandro.pratesi@unifi.it (A. Pratesi), luigi.messori@unifi.it (L. Messori).




Fig. 1. Structure of complex I.

were measured in vitro against a small panel of cancer cell lines with rather encouraging results.

2. Materials and methods

2.1. Spectrophotometric experiments

UV–vis absorption spectra were recorded on a Varian Cary 50 UV–Vis spectrophotometer (Varian, Palo Alto, CA, USA) in the range of 200–700 nm. Stock solution of **I** (3×10^{-3} M) was prepared by dissolving the complex under investigation in DMSO.

For stability studies in solution, UV–Vis measurements were performed by diluting the compound's stock solutions to 3×10^{-4} M in DMSO. Spectra were collected during 24 and 72 h at room temperature, operating in 10 min intervals during the first hour and in 1 h intervals afterward.

2.2. GSH and Cys interaction studies – electrospray ionization mass spectrometry

The stock solution of **I** was prepared in DMSO at 1 mM and stored at -20 °C until usage. DMSO stock solutions (10 mM) of GSH and Cys were prepared. 100 μ L of these solutions were added, separately, to 10 μ L of the stock solution of **I** in order to obtain a 10:1 ratio. The mixtures were diluted with DMSO at a final concentration of 10^{-4} M of **I**. Samples were incubated at 37 °C for 24 h.

Electrospray ionization mass spectra of the mixtures were recorded from samples generated through 20-fold dilution with H₂O/CH₃CN 1:1 in an LTQ-Orbitrap high-resolution mass spectrometer (Thermo, San Jose, CA, USA), equipped with a conventional ESI source (direct introduction, flow rate 5 μ L/min). The following standardized working conditions were applied: spray voltage 3.1 kV, tube lens voltage 230 V, capillary voltage 45 V, and capillary temperature 220 °C. Sheath and auxiliary gases were set at 17 au and 1 au, respectively. Data was acquired with a nominal resolution of 100,000 (at m/z 400), using Xcalibur 2.0 software (Thermo).

2.3. Biological experiments

2.3.1. Cell cultures

MDAMB231, MCF7 cell lines were cultured in DMEM (Euroclone; Milan, Italy) with 10% Fetal Bovine Serum (FBS) (Euroclone Defined; Euroclone; Milan, Italy). HCT-116, FLG 29.1, L929 and HL60 were cultured in RPMI 1640 (Euroclone; Milan, Italy) with 10% Fetal Bovine Serum (FBS) (Euroclone Defined; Euroclone; Milan, Italy). HCT116 cells were kindly provided by Dr. R. Falcioni (Regina Elena Cancer Institute, Roma). We cultured the cell lines at 37 °C under a humidified atmosphere in 5% CO₂ in air.

2.3.2. Pharmacology experiments

Cells were seeded in a 96-well flat-bottomed plate (Corning-Costar, Corning, NY, USA) at a cell density of 1×10^4 cells per well in either RPMI or DMEM complete medium. The compound **I** was used, after solubilisation in water without DMSO, in range of concentration of 0–200 nM. After 24 h and 48 h, viable cells (determined by Trypan blue exclusion) were counted in triplicate using a haemocytometer. Each experimental point represents the mean of a single experiment carried out in triplicate.

2.3.3. Trypan blue assay

Cells viability was assessed by the Trypan blue exclusion assay. In brief, 10 μ L of 0.4% trypan blue solution was added to 10 μ L cell suspensions in culture medium. The suspension was gently mixed and transferred to a haemocytometer. Viable and dead cells were identified and counted under a light microscope. Blue cells failing to exclude the dyes were considered nonviable, and transparent cells were considered viable. The percentage of viable cells was calculated on the basis of the total number of cells (viable plus nonviable).

The IC₅₀ value (i.e., the dose that caused apoptosis of 50% of cells) was calculated by fitting the data points (after 24 h and 48 h of incubation) with a sigmoidal curve using Calcsyn software (Biosoft, Cambridge, UK).

3. Results and discussion

3.1. Chemistry: solution behaviour and reactivity

The solubility profile of complex **I** was investigated in a variety of solvents. Beyond being soluble in some organic solvents like DCM and acetone, this compound also manifested an appreciable solubility in DMSO and, also, in DMSO/aqueous buffer mixtures.

The stability behaviour of the triplatinum cluster in these latter solvents was monitored over time by UV visible spectroscopy. As shown in Fig. 2, this compound exhibits a typical absorption spectrum in the UV–Visible, characterised by the presence of four resolved bands at 280, 310, 330 and 380 nm. The triplatinum species was found to be stable during the first 12 h at 25 °C.

Anyway, upon extending the stability study in DMSO up to 72 h at 25 °C, some major changes in the UV–Vis spectrum became evident (see Fig. 2). In fact, a decrease of the bands located at 310, 330 and 380 nm is detected with a concomitant growing up of the bands at 250 and 440 nm. In addition, an isosbestic point is present, in the visible, at 420 nm.




Fig. 2. UV–Vis absorption spectra of a 3×10^{-4} M solution of **I** in DMSO recorded during 72 h. The group of traces included with the red line are referred to the first 12 h; blue line, 24 h; green line, 48 h; pink line, 72 h.

Afterward, we analysed the reactivity of **I** with small proteins and a few low molecular weight biomolecules. ESI-MS turned out to be an optimal tool for this kind of investigation according to previous experience of our laboratory [14–16]. The ESI-MS spectrum of **I**, in CH₃CN solution, reveals the characteristic isotopic pattern (see Fig. 3). No adduct formation was detected by ESI-MS when **I** was challenged against the two model proteins *cyt-c* and *lysozyme*, even after long incubation times. Yet, when reacted with small sulfur-containing ligands, a clear reactivity was highlighted. In particular, quantitative formation of stable derivatives with GSH and Cys was demonstrated by the ESI-MS experiments shown in Fig. 4.

Indeed, from inspection of the ESI-MS spectra shown in Fig. 4, the high reactivity of **I** toward both sulfur-containing small molecules is unambiguously documented. In fact, the peak at m/z 1383.31 (panel A) could be assigned to the **I**-GSH complex, with the loss of only one CO group. In the same manner, the peak at m/z 1197.25 (panel C) was attributed to the **I**-Cys adduct. Even in this case the loss of one CO group occurs that is most probably displaced by a sulfur donor. Analysis of the measured isotopic pattern confirmed the formation of the two mentioned adducts (panel B and D, respectively). In addition, either in case of GSH or of Cys, the ESI-MS experiments did not reveal the presence of unreacted **I** nor the formation of adducts of **I** with more than one molecule of GSH or Cys.

3.2. Biological studies

Having documented such an interesting behaviour of complex **I** in aqueous solution and its selectivity in biomolecular reactions, we decided to evaluate the cellular effects of complex **I** against a representative panel of cancer cell lines. The cancer cell panel included the following cell lines: MDAMB231 and MCF7 (human breast cancer), HL60 and FLG 29.1 (human acute myeloid leukemia), and a series of cell lines (human colorectal adenocarcinoma) showing different sensitivity to cisplatin i.e. HCT116, HCT8 and HT29.

To determine the cytotoxic effect of the triplatinum cluster on the above cancer lines we used the Trypan blue method as detailed in the experimental section. Following a preliminary appreciation of its potent antiproliferative effects, the biological activity of compound **I** was assessed at seven different concentrations in the nanomolar range, (i.e. 0.5 nM, 1 nM, 5 nM, 10 nM, 20 nM, 50 nM, 100 nM) after 24 and 48 h incubation. Analysis of the corresponding growth curves according to Chou Talalay algorithm allows determination of the respective IC₅₀ values, that are reported in Table 1. The extremely high antiproliferative potential of this compound is thus demonstrated. The IC₅₀ values are higher after 48 h of treatment, suggesting that the tested cancer cells are able to reverse, i.e. repair, at least partially, the insult. As this behaviour differs from cisplatin for which IC₅₀ values at 48 h are generally smaller than those recorded at 24 h, these results offer some initial evidence that the mode of action of the triplatinum cluster markedly differs from cisplatin.




Fig. 3. ESI-MS spectrum of **I**; panel A – measured, panel B – theoretical.




Fig. 4. ESI-MS spectra of **I** in DMSO incubated with GSH (A) and Cys (B) with their characteristic isotopic patterns (B and D, respectively).

Moreover, the cytotoxic activity against non-cancerous cell line L929 (mouse fibroblast), was also assessed in the same conditions. Normal cells turned out to be less sensitive to compound **I** than cancer cells (IC_{50} 167.3 \pm 8.67 nM). Tumour selectivity values, calculated as the IC_{50} values for primary cultures divided by the IC_{50} values for the cancer cells, are in the range between 19.25 (MCF7) and 3.68 (HCT116). These data clearly indicate that the experimental compound **I** possesses a moderate to pronounced selectivity for tumour cells. In the same experimental conditions three cancer cell lines, HCT116, HT29 and HCT8 were also tested that possess variable sensitivity to cisplatin, respectively (see Table 1). The obtained data clearly showed that cell line less sensitive to cisplatin has the lower IC_{50} for compound **I**.

The cell lines were exposed to increasing concentrations of compound **I** in the range 0–200 nM. After 24 and 48 h, viable cells (determined by Trypan blue exclusion) were counted in triplicate using a haemocytometer. Each experimental point represents the mean of four samples carried out in three separate experiments.

We next evaluated the effect of compound **I** in the induction of apoptosis in HCT116 cells by the Annexin/PI test. The treatment with compound **I** for 48 h caused an evident induction of apoptosis as shown in Fig. 5.

4. Conclusions

From these initial studies it can be stated that the investigated triplatinum cluster manifests an appreciable stability within various physiological media and exhibits, at the same time, very potent antiproliferative effects in a panel of representative tumour cell lines. It is remarkable that a very potent cytotoxic action is detected also toward the triple negative MDAMB231 cells, a kind of cancer cell line often refractory to several medical treatments. It will be of interest in the next future to perform further studies to better understand the mode of action of this novel and peculiar Pt complex. It is particularly relevant to determine whether the cluster acts in its intact form, i.e. as a trimetallic

Table 1
 IC_{50} values for compound **I** in a panel of leukemia cell lines and solid tumour cell lines.

Cell line	Type	IC_{50} (nM) 24 h	IC_{50} (nM) 48 h	IC_{50} Cisplatin (μ M)
MDAMB231	Breast cancer	16.3 \pm 0.8	19.6 \pm 1.1	82.5 \pm 3.2
MCF7	Breast cancer	8.7 \pm 1.1	32.1 \pm 1.2	–
HL60	Acute leukemia	22.5 \pm 0.8	37.8 \pm 1.4	–
FLG 29.1	Acute leukemia	31.6 \pm 0.9	69.5 \pm 2.4	24.4 \pm 0.8
HCT116	Colorectal adenocarcinoma	45.4 \pm 6.5	61.2 \pm 3.7	25.5 \pm 2.1
HT-29	Colorectal adenocarcinoma	130.0 \pm 14.5	–	16.6 \pm 0.9
HCT-8	Colorectal adenocarcinoma	92.0 \pm 7.1	–	8.7 \pm 1.4




Fig. 5. Effect of compound I on apoptosis induction of HCT116. Effect of compound I given at IC_{50} value on HCT116 cells after 48 h of treatment. Two representative panels are reported. Left panel = control (early apoptotic cells, Annexin +/PI-: 0%; late apoptotic cells, Annexin +/PI+: 0%); right panel = treated with compound I (early apoptotic cells, Annexin +/PI-: 12%; late apoptotic cells, Annexin +/PI+: 39%).

species, or undergoes degradation in the cellular environment releasing monometallic Pt species.

Abbreviations

Cys	cysteine
DCM	dichloromethane
DMEM	Dulbecco's Modified Eagle Medium
DMSO	dimethyl sulfoxide
ESI-MS	electrospray ionization mass spectrometry
GSH	reduced glutathione
HER2	human epidermal growth factor receptor 2
MCF 7	Michigan Cancer Foundation-7
PI	propidium iodide
RPMI	Roswell Park Memorial Institute medium

Acknowledgements

The Fondazione Umberto Veronesi is gratefully acknowledged for the financial support to AP. Beneficentia Stiftung (Vaduz, Liechtenstein), CIRCMSB, COST Action CM1105 and AIRC IG-16049 are also acknowledged for generous financial support.

References

- [1] G. Manca, A. Ienco, A. Messaoudi, C. Mealli, *Inorg. Chim. Acta* 424 (2015) 322–328.
- [2] R. Bender, R. Welter, P. Braunstein, *Inorg. Chim. Acta* 424 (2015) 20–28.
- [3] M. Molon, K. Dilchert, C. Gemel, R.W. Seidel, J. Schaumann, R.A. Fischer, *Inorg. Chem.* 52 (2013) 14275–14283.
- [4] J.N. Tiwari, K. Nath, S. Kumar, R.N. Tiwari, K.C. Kemp, N.H. Le, D.H. Youn, J.S. Lee, K.S. Kim, *Nat. Commun.* 4 (2013) 3221/1–3221/7.
- [5] J. Yan, H. Su, H. Yang, S. Malola, S. Lin, H. Hakkinen, N. Zheng, *J. Am. Chem. Soc.* 137 (2015) 11880–11883.
- [6] Y. Wang, P.-A. Deyris, T. Caneque, F. Blanchard, Y. Li, F. Bigi, R. Maggi, S. Blanchard, G. Maestri, M. Malacria, *Chem. Eur. J.* 21 (2015) 12271–12274.
- [7] C. Archambault, R. Bender, P. Braunstein, Y. Dusaousy, R. Welter, *Dalton Trans.* 43 (2014) 8609–8619.
- [8] H. Arai, M. Takahashi, M. Nanjo, K. Mochida, *Organometallics* 30 (2011) 917–920.
- [9] P. Maity, S. Basu, S. Bhaduri, G.K. Lahiri, *Adv. Synth. Catal.* 349 (2007) (1955–196).
- [10] T. Imaoka, H. Kitazawa, W.-J. Chun, K. Yamamoto, *Angew. Chem. Int. Ed.* 54 (2015) 9810–9815.
- [11] Y. Tang, Z. Lu, W. Chen, W. Li, X. Dai, *Phys. Chem. Chem. Phys.* 17 (2015) 11598–11608.
- [12] V. Bonuccelli, T. Funaioli, P. Leoni, F. Marchetti, L. Marchetti, *Inorg. Chem.* 52 (2013) 8759–8769.
- [13] V. Bonuccelli, T. Funaioli, P. Leoni, L. Marchetti, S. Zacchini, *Dalton Trans.* 42 (2013) 16898–16908.
- [14] L. Messori, T. Marzo, R.N.F. Sanches, Hanif-Ur-Rehman, D. de Oliveira Silva, A. Merlino, *Angew. Chem. Int. Ed.* 53 (2014) 6172–6175.
- [15] L. Messori, T. Marzo, E. Michelucci, I. Russo Krauss, C. Navarro-Ranninger, A.G. Quiroga, A. Merlino, *Inorg. Chem.* 53 (2014) 7806–7808.
- [16] L. Messori, T. Marzo, A. Merlino, *Chem. Commun.* 50 (2014) 8360–8362.